BACKGROUND: The hepatocyte growth factor (HGF)/c-Met pathway is often dysregulated in non-small-cell lung cancer (NSCLC). HGF activation of c-Met induces cyclooxygenase-2 (COX-2), resulting in downstream stimulation by prostaglandin E2 of additional pathways. Targeting both c-Met and COX-2 might lead to enhanced antitumor effects by blocking signaling upstream and downstream of c-Met. METHODS: Effects of crizotinib or celecoxib alone or in combination were tested in NSCLC cells in vitro and in mice transgenic for airway expression of human HGF. RESULTS: Proliferation and invasion of NSCLC cells treated with a combination of crizotinib and celecoxib were significantly lower compared with single treatments. Transgenic mice showed enhanced COX-2 expression localized to preneoplastic areas following exposure to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, which was not present without carcinogen exposure. This shows that COX-2 activity is present during lung tumor development in a high HGF environment. After 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone treatment, a significant decrease in the number of lung tumors per animal was observed after 13-week treatments of crizotinib, celecoxib, or the combination compared with placebo (p < 0.001). With combination treatment, the number of tumors was also significantly lower than single agent treatment (p < 0.001). In the resulting lung tumors, P-c-Met, COX-2, prostaglandin E2, and P-MAPK were significantly downmodulated by combination treatment compared with single treatment. Expression of the epithelial-mesenchymal transition markers E-cadherin and snail was also modulated by combination treatment. CONCLUSIONS: In the presence of high HGF, dual inhibition of c-Met and COX-2 may enhance antitumor effects. This combination may have clinical potential in NSCLCs with high HGF/c-Met expression or epithelial-mesenchymal transition phenotype.
BACKGROUND: The hepatocyte growth factor (HGF)/c-Met pathway is often dysregulated in non-small-cell lung cancer (NSCLC). HGF activation of c-Met induces cyclooxygenase-2 (COX-2), resulting in downstream stimulation by prostaglandin E2 of additional pathways. Targeting both c-Met and COX-2 might lead to enhanced antitumor effects by blocking signaling upstream and downstream of c-Met. METHODS: Effects of crizotinib or celecoxib alone or in combination were tested in NSCLC cells in vitro and in micetransgenic for airway expression of humanHGF. RESULTS: Proliferation and invasion of NSCLC cells treated with a combination of crizotinib and celecoxib were significantly lower compared with single treatments. Transgenic mice showed enhanced COX-2 expression localized to preneoplastic areas following exposure to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, which was not present without carcinogen exposure. This shows that COX-2 activity is present during lung tumor development in a high HGF environment. After 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone treatment, a significant decrease in the number of lung tumors per animal was observed after 13-week treatments of crizotinib, celecoxib, or the combination compared with placebo (p < 0.001). With combination treatment, the number of tumors was also significantly lower than single agent treatment (p < 0.001). In the resulting lung tumors, P-c-Met, COX-2, prostaglandin E2, and P-MAPK were significantly downmodulated by combination treatment compared with single treatment. Expression of the epithelial-mesenchymal transition markers E-cadherin and snail was also modulated by combination treatment. CONCLUSIONS: In the presence of high HGF, dual inhibition of c-Met and COX-2 may enhance antitumor effects. This combination may have clinical potential in NSCLCs with high HGF/c-Met expression or epithelial-mesenchymal transition phenotype.
Authors: Shirish M Gadgeel; John C Ruckdeschel; Elisabeth I Heath; Lance K Heilbrun; Raghu Venkatramanamoorthy; Antoinette Wozniak Journal: J Thorac Oncol Date: 2007-04 Impact factor: 15.609
Authors: Mariam Dohadwala; Seok-Chul Yang; Jie Luo; Sherven Sharma; Raj K Batra; Min Huang; Ying Lin; Lee Goodglick; Kostyantyn Krysan; Michael C Fishbein; Longsheng Hong; Chi Lai; Robert B Cameron; Robert M Gemmill; Harry A Drabkin; Steven M Dubinett Journal: Cancer Res Date: 2006-05-15 Impact factor: 12.701
Authors: Dong M Shin; Hongzheng Zhang; Nabil F Saba; Amy Y Chen; Sreenivas Nannapaneni; A R M Ruhul Amin; Susan Müller; Melinda Lewis; Gabriel Sica; Scott Kono; Johann C Brandes; William J Grist; Rachel Moreno-Williams; Jonathan J Beitler; Sufi M Thomas; Zhengjia Chen; Hyung Ju C Shin; Jennifer R Grandis; Fadlo R Khuri; Zhuo Georgia Chen Journal: Clin Cancer Res Date: 2013-02-19 Impact factor: 12.531
Authors: Shibo Fu; Michael Rivera; Eric C Ko; Andrew G Sikora; Chien-Ting Chen; Ha Linh Vu; David Cannan; Samuel Eisenstein; Barry S Rosenstein; Julio Aguirre-Ghiso; Shu-Hsia Chen; Johnny Kao Journal: J Cell Sci Ther Date: 2011-10-13
Authors: Laura P Stabile; Jennifer S Lyker; Stephanie R Land; Sanja Dacic; Beth A Zamboni; Jill M Siegfried Journal: Carcinogenesis Date: 2006-03-02 Impact factor: 4.944
Authors: Karen L Reckamp; Brian K Gardner; Robert A Figlin; David Elashoff; Kostyantyn Krysan; Mariam Dohadwala; Jenny Mao; Sherven Sharma; Landon Inge; Ayyappan Rajasekaran; Steven M Dubinett Journal: J Thorac Oncol Date: 2008-02 Impact factor: 15.609
Authors: Abu Bakar Siddique; Phillip C S R Kilgore; Afsana Tajmim; Sitanshu S Singh; Sharon A Meyer; Seetharama D Jois; Urska Cvek; Marjan Trutschl; Khalid A El Sayed Journal: Nutrients Date: 2020-06-11 Impact factor: 5.717
Authors: Laura P Stabile; Vinod Kumar; Autumn Gaither-Davis; Eric H Huang; Frank P Vendetti; Princey Devadassan; Sanja Dacic; Riyue Bao; Richard A Steinman; Timothy F Burns; Christopher J Bakkenist Journal: JCI Insight Date: 2021-02-08